1. Jpn J Clin Oncol. 2010 Oct 14. [Epub ahead of print]

Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma
Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma
Working Party (KMMWP) Retrospective Study.

Kim SJ, Kim K, Do YR, Bae SH, Yang DH, Lee JJ.

1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School
of Medicine, Seoul.

OBJECTIVE: Acyclovir prophylaxis has been considered as mandatory for patients
receiving bortezomib because herpes zoster is a common adverse event associated
with the use of bortezomib. Although the minimal effective dose of acyclovir for 
prophylaxis has not yet established, the efficacy of low-dose acyclovir
prophylaxis, 400 mg once daily, has been suggested. METHODS: We retrospectively
reviewed the patients receiving the low-dose acyclovir which was defined as the
once daily administration of acyclovir 400 or 200 mg. All patients received
bortezomib-containing chemotherapy in the setting of relapsed or refractory
myeloma. RESULTS: Eighty patients received bortezomib-containing treatment as a
salvage therapy. All patients received at least one or more treatments prior to
bortezomib treatment, including autologous stem cell transplantation. Sixty-one
patients received 400 mg of acyclovir once daily while 19 patients received 200
mg. Although seven cases of herpes zoster were observed from 80 patients (7/80,
8.75%), two cases of herpes zoster received 400 mg during the limited period from
the first to the fourth cycle, and the other five received 200 mg. Therefore,
there was no herpes zoster in patients who received 400 mg of acyclovir till the 
last cycle of bortezomib treatment. There were no adverse events associated with 
the use of acyclovir prophylaxis. CONCLUSIONS: The administration of acyclovir
400 mg once daily during the bortezomib treatment is an effective prophylaxis for
herpes zoster in patients receiving bortezomib irrespective of disease state and 
the type of chemotherapy regimen.


PMID: 20947927 [PubMed - as supplied by publisher]


2. Vaccine. 2010 Oct 11. [Epub ahead of print]

Herpes zoster: Burden of disease in France.

Chiappe SG, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow O,
Blanchon T, Hanslik T.

INSERM, U707, F-75012 Paris, France; UPMC Univ Paris 06, UMR-S, F-75005 Paris,
France.

This work provides estimates of HZ incidence and HZ-related hospitalization and
mortality rates in France, where no immunization programme has been implemented. 
Herpes zoster data is obtained from the Sentinelles surveillance general
practitioners (GPs) network, the PMSI Data processing centre for hospital
discharges and from the French National Mortality Database (INSERM CepiDC). The
yearly HZ incidence rate averaged 382 cases per 100,000 inhabitants (95% CI
364-405) and exponentially increased with age. The annual rates of
hospitalizations and mortality due to HZ varied from 4.14±0.32 to 14.42±0.39 and 
from 0.11±0.03 to 0.29±0.04 per 100,000 inhabitants, respectively, depending on
whether HZ was coded in a 'primary' or 'primary or associated' diagnosis. One or 
more factors of immunodepression occurred in 43.4% of hospitalized cases and in
21.6% HZ-related deaths.


PMID: 20946861 [PubMed - as supplied by publisher]


3. BMC Neurol. 2010 Oct 11;10(1):92. [Epub ahead of print]

Effect of duration of postherpetic neuralgia on efficacy analyses in a
multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch
evaluated for the treatment of postherpetic neuralgia.

Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF.

ABSTRACT: BACKGROUND: Postherpetic neuralgia (PHN) is a painful and difficult to 
treat complication of acute herpes zoster. Current treatment options provide only
partial relief and are often limited by poor tolerability. We evaluated the
safety and efficacy of a single 60-minute application of NGX-4010, an 8%
capsaicin patch, in patients with PHN. METHODS: This multicenter, double-blind,
controlled study randomized 155 patients 2:1 to receive either NGX-4010 or a
0.04% capsaicin control patch. Patients were at least 18 years old with PHN for
at least 3 months, and an average Numeric Pain Rating Scale (NPRS) score of 3 to 
9. The primary efficacy endpoint was the percentage change in NPRS score from
baseline to weeks 2-8. RESULTS: The mean percent reduction in "average pain for
the past 24 hours" NPRS scores from baseline to weeks 2-8 was greater in the
NGX-4010 group (36.5%) compared with control (29.9%) although the difference was 
not significant (p=0.296). PGIC analysis demonstrated that more NGX-4010
recipients considered themselves improved (much, or very much) compared with
control at weeks 8 and 12, but the differences did not reach statistical
significance. Post hoc analyses of patients with PHN for at least 6 months showed
significantly greater reductions in "average pain for the past 24 hours" NPRS
scores from baseline to weeks 2-8 in NGX-4010 patients compared to controls
(37.6% versus 23.4%; p=0.0291). PGIC analysis in this subgroup demonstrated that 
significantly more NGX-4010 recipients considered themselves much or very much
improved compared with control at week 12 (40% versus 20%; p=0.0403;).
CONCLUSIONS: Although treatment appeared to be safe and well tolerated, a single 
60-minute application of NGX-4010 failed to show efficacy in this study which
included patients with PHN for less than 6 months. Large reductions in pain
observed among control patients with pain for less than 6 months may have been
due to spontaneous resolution of PHN, may have confounded the results of the
prespecified analyses, and should be taken into account when designing PHN
studies. Trial Registration: NCT00068081.


PMID: 20937130 [PubMed - as supplied by publisher]


4. BMC Med. 2010 Oct 11;8(1):58. [Epub ahead of print]

Predictors of pain intensity and persistence in a prospective Italian cohort of
patients with herpes zoster: relevance of smoking, trauma and antiviral therapy.

Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, Agostinone
A, Di Masi F, Congedo G, D'Antonio D, Granchelli C, D'Amario C, Carunchio C,
Pippa L, Manzoli L, Volpi A, Study Group VP.

ABSTRACT: BACKGROUND: Herpes zoster (HZ) is a common disease, characterized by
rash-associated localized pain. Its main complication, post-herpetic neuralgia
(PHN), is difficult to treat and may last for months to years in the wake of rash
resolution. Uncertainties remain as to the knowledge of predictors of HZ-related 
pain, including the role of antiviral therapy in preventing PHN in ordinary
clinical practice. This prospective cohort study was aimed at investigating pain 
intensity at HZ presentation and its correlates, as well as the incidence of PHN 
and its predictors. METHODS: Patients diagnosed with HZ were consecutively
enrolled by a network of Italian General Practitioners and Hospital Units in the 
health district of Pescara, Italy, over two years. Uncertain cases were referred 
for microbiological investigation. Data were collected through electronic case
report form (e-CRFs) at enrolment and at 1, 3, 6 and 12 months after enrolment.
Pain intensity was coded on a five-degree semi-quantitative scale at each time
point. PHN was defined as pain of any intensity during follow-up and quantified
using an area-under-the-curve (AUC) method. RESULTS: Four hundred and forty-one
patients composed the final sample. Mean age was 58.1 years (SD = 20.4 years);
43.5% of patients were males; 7.9% did not receive prescription of antivirals.
Intense/very intense pain at presentation was reported by 25.2% of patients and
was significantly associated with female gender, older age, cigarette smoking,
trauma and/or surgery at HZ site (logistic regression). PHN was diagnosed in
51.2% of patients at one month and in 30.0% of patients at three months. PHN was 
significantly associated with pain intensity at presentation, age, smoking,
trauma and missed antiviral prescription (generalized estimating equations
model). The same factors were also independent predictors of the overall pain
burden as described by the AUC method (linear regression). CONCLUSIONS: Smoking, 
traumas and surgery at the HZ site emerged as new predictors of both HZ-related
pain intensity and persistence, opening new perspectives in the prevention of
HZ-related pain. An independent line of evidence was provided for the efficacy of
antiviral therapy in preventing PHN and reducing total pain burden.


PMID: 20937086 [PubMed - as supplied by publisher]


5. J Infect Dis. 2010 Oct 7. [Epub ahead of print]

A 2009 Varicella Outbreak in a Connecticut Residential Facility for Adults with
Intellectual Disability.

Leung J, Kudish K, Wang C, Moore L, Gacek P, Radford K, Lopez A, Sosa L, Schmid
DX, Cartter M, Bialek S.

National Center for Immunization and Respiratory Diseases, 2Epidemic Intelligence
Service, Centers for Disease Control and Prevention, and 3Centers for Diseases
Control and Prevention/Council of State and Territorial Epidemiologists Applied
Epidemiology Fellowship Program, Atlanta, Georgia; 4 Connecticut Department of
Public Health, Hartford, Connecticut.

We investigated a varicella outbreak in a residential facility for adults with
intellectual disabilities. A case of varicella was defined as a generalized
maculopapular rash that developed in a facility resident or employee.
Immunoglobulin M testing was conducted on serologic samples, and polymerase chain
reaction testing was performed on environmental and skin lesion samples. Eleven
cases were identified among 70 residents and 2 among ∼145 staff. An
unrecognized case of herpes zoster was the likely source. Case patients first
entered any residential facility at a younger age than non‐case residents 
(9.5 vs 15.0 years; [Formula: see text]). Varicella zoster virus DNA was detected
2 months after the outbreak in environmental samples obtained from case
patients’ residences. This outbreak exemplifies the potential for
at‐risk pockets of varicella‐susceptible adults, especially among
those who have lived in residential facilities from a young age. Evidence of
immunity should be verified for all adults and healthcare staff in similar
residential settings.


PMID: 20929354 [PubMed - as supplied by publisher]


6. Hautarzt. 2010 Oct 8. [Epub ahead of print]

[Disseminated papules in a patient with acute myeloid leukemia.]

[Article in German]

Ceric-Dehdari P, Houcinat Y, Berger TG.

Department of Dermatology, Tawam Hospital in affiliation with Johns Hopkins
Medicine, Al Ain, United Arab Emirates.

Cryptococcosis most commonly occurs in immunosuppressed patients. The pathogen is
the yeast Cryptococcus neoformans. This article reports on the case of a
20-year-old female patient with acute myeloid leukemia who suddenly developed
disseminated livid red papules and papulovesicles. The clinical picture and in
particular the histopathology findings led to the diagnosis of cutaneous
cryptococcosis, which was successfully treated with amphotericin B. For the
differential diagnosis generalized herpes zoster, erythema exudativum multiforme 
and disseminated molluscum contagiosum must be considered. To confirm the
diagnosis attempts can also be made to culture the pathogen from skin biopsy
preparations. Furthermore, fungal spores can be rapidly and simply detected with 
the Tzanck test.


PMID: 20927503 [PubMed - as supplied by publisher]


7. Epidemiol Mikrobiol Imunol. 2010 Aug;59(3):138-46.

[Herpes zoster in the Czech Republic--epidemiology and clinical manifestations]

[Article in Czech]

Smetana J, Salavec M, Bostikova V, Chlibek R, Bostik P, Hanovcova I, Vackova M,
Matulkova P, Splino M.

Katedra epidemiologie, Fakulta vojenskeho zdravotnictvi UO, Hradec Kralove.
smetana@pmfhk.cz

Herpes zoster (shingles) is a viral infection of the skin that manifests itself
as painful, unilateral vesicular rash. The causative agent is varicella-zoster
virus (VZV). Primary infection with VZV causes chickenpox, a common childhood
infection, and then the virus lies dormant in the sensory neural ganglia,
reactivating to cause shingles. The most important complications are neurological
disorders (in particular postherpetic neuralgia) and eye disorders. First-line
therapy are antiviral agents. A single vaccine has been registered to date.
Herpes zoster occurs sporadically in the Czech Republic and its incidence is
long-term stable. In 1990-2008 the average annual incidence was 6306 cases (61.3 
cases/100,000 population), with the lowest number of 5511 cases (53.5/100,000)
reported in 1991 and the highest number of 6,894 cases (67.6/100,000) reported in
2002. The incidence rate in females (69.9/100,000) was 1.4 times as high as in
males (49.5/100,000). From the age perspective, the elderly are at a considerably
higher risk of developing shingles. In 2008, the incidence rate was the highest
in the age group 70 years (155.0/100,000). Nevertheless, the beginning of the
upward trend is seen in the age group 45-49 years. Herpes zoster does not show
any seasonal trend.


PMID: 20925251 [PubMed - in process]


8. Indian J Dermatol Venereol Leprol. 1998 Nov-Dec;64(6):310.

Shield as topical ointment in herpes zoster.

Kar S.

Dept of Skin and V.D, MG Institute of Medical Sciences, Sevagram, India.

PMID: 20921810 [PubMed - in process]


9. Indian J Dermatol Venereol Leprol. 1998 Jul-Aug;64(4):169-72.

Natural history of herpes zoster in the era of AIDS.

Dandavate V, Hira S, Oberai C.

From the Departments of Skin/ STD, Sir J. J. Hospital, Mumbai AIDS Research and
Control Centre (ARCON), Sir J. J. Hospital, Mumbai and the University of
Texas-Houston, USA.

Seventy-four consecutive patients with herpes zoster (HZ) in Mumbai were
recruited into the study to determine its natural history. Thirty-five (47.3%)
with HZ were infected with HIV-1/2. HZ+HIV+ and HZ+HIV- were demographically
similar but HZ+HIV+ were clinically different; the latter were characterised by
multidermatomal involvement of thoracic dermatomes below T6 or that of trigeminal
nerve, recurrent episodes, bullous lesions and 17/35 had associated illnesses
such as severe weight loss, recurrent fever, chronic cough, active tuberculosis
and oral candidiasis. Significant differences in the course of healing, incidence
of secondary bacterial infection and scaring emerged between the two groups after
day-10. HZ+HIV+ individuals had vesicles and ulcers persisting for significantly 
longer time with frequent sequelae of post inflammatory pigmentation and post
herpetic neuralgia. In areas where resources are limited for health information, 
such clinical differences between HZ+HIV+ and HZ+HIV- will serve to identify
individuals with HIV infection in dermatologic clinic. These findings will also
be helpful for early diagnosis of HIV infection, associated opportunistic
infections and prevent their secondary transmission through appropriate
interventions.


PMID: 20921754 [PubMed - in process]


10. Indian J Dermatol Venereol Leprol. 1999 Nov-Dec;65(6):294-5.

Herpes zoster in a 9 - month - old infant.

Jain A, Singal A, Baruah MC.

From the Department of Dermatology & STD, University College of Medical Sciences 
& GTB Hospital, Shahdara, Delhi - 110 095, India.

PMID: 20921693 [PubMed - in process]


11. CMAJ. 2010 Oct 4. [Epub ahead of print]

The impact of herpes zoster and postherpetic neuralgia on health-related quality 
of life: a prospective study.

Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D,
Blanchette C, Mansi JA.

BACKGROUND: Vaccination against herpes zoster is being considered in many
countries. We conducted a multi centre prospective study to describe the impact
of herpes zoster and postherpetic neuralgia on health-related quality of life.
METHODS: From October 2005 to July 2006, 261 outpatients aged 50 years or older
with herpes zoster were recruited from the clinical practices of 83 physicians
within 14 days after rash onset. The Zoster Brief Pain Inventory was used to
measure severity of pain and interference with activities of daily living because
of pain. The EuroQol EQ-5D assessment tool was used to measure quality of life.
These outcomes were assessed at recruitment and on days 7, 14, 21, 30, 60, 90,
120, 150 and 180 following recruitment. RESULTS: Acute herpes zoster interfered
in all health domains, especially sleep (64% of participants), enjoyment of life 
(58%) and general activities (53%). The median duration of pain was 32.5 days.
The median duration of interference with activities of daily living because of
pain varied between 27 and 30 days. Overall, 24% of the participants had
postherpetic neuralgia (pain for more than 90 days after rash onset). Anxiety and
depression, enjoyment of life, mood and sleep were most frequently affected
during the postherpetic neuralgia period. The mean EQ-5D score was 0.59 at
enrolment and remained at 0.67 at all follow-up points among participants who
reported clinically significant pain. INTERPRETATION: These data support the need
for preventive strategies and additional early intervention to reduce the burden 
of herpes zoster and postherpetic neuralgia.


PMID: 20921251 [PubMed - as supplied by publisher]


12. CMAJ. 2010 Oct 4. [Epub ahead of print]

Herpes zoster and postherpetic neuralgia.

Watson CP.

PMID: 20921245 [PubMed - as supplied by publisher]


13. Am Fam Physician. 2010 Oct 1;82(7):815-6.

Acute onset vesicular rash. Herpes zoster.

Ibrahimi OA, Sakamoto GK, Lee JJ.

Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
oibrahimi@partners.org

PMID: 20879705 [PubMed - in process]


14. J Gen Intern Med. 2010 Sep 29. [Epub ahead of print]

Syndrome of Inappropriate Secretion of Antidiuretic Hormone Associated with
Localized Herpes Zoster Ophthalmicus.

Wang CC, Shiang JC, Chen JT, Lin SH.

Division of Nephrology, Department of Medicine, Tri-Service General Hospital,
Taipei, Taiwan, Republic of China.

The syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
associated with localized herpes zoster is rarely reported and may be
under-appreciated. We describe two diabetic men with herpes zoster ophthalmicus
(HZO) who developed hyponatremia (114 and 116 mmol/L) during acute illness. Both 
were euvolemic and had elevated urine osmolality (435 and 368 mmol/kg.H(2)O) and 
sodium (Na(+)) concentration (61 and 63 mmol/L) along with normal cardiac, renal,
liver, and endocrine function consistent with the diagnosis of SIADH. Thorough
investigation for other causes of SIADH, including detailed physical examination,
laboratory studies, and computed tomography of the brain, chest, and abdomen,
were negative. Despite antiviral therapy (acyclovir) for herpes zoster,
ophthalmoplegia, keratitis, and post-herpetic neuralgia (PHN) developed. Even
with fluid restriction and high salt diet, SIADH lasted for 3 to 4 months and
resolved concomitantly with resolution of PHN, suggesting an association between 
SIADH and HZO. These two cases raise the potential for herpes zoster infection,
especially HZO, to involve the regulatory pathway of ADH secretion, contributing 
to SIADH. The presence of PHN, which reflects greater neural damage may, at least
in part, explain the prolonged ADH secretion and hyponatremia.


PMID: 20878495 [PubMed - as supplied by publisher]


15. J Clin Aesthet Dermatol. 2010 Sep;3(9):20-9.

The Expression of Toll-like Receptors in Dermatological Diseases and the
Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.

Valins W, Amini S, Berman B.

Toll-like receptors are a group of glycoproteins located mostly in cellular
membranes, capable of recognizing certain molecules in exogenous microorganisms
and initiating immune responses against them through the activation of several
intracellular signaling pathways. Toll-like receptors can be stimulated when an
inflammatory reaction is needed for the treatment of conditions, such as viral
infections or skin cancer, or can be inhibited when a reduction of inflammation
is necessary for the treatment of conditions, such as rheumatoid arthritis,
systemic lupus erythematosus, and septic shock. In the human skin, keratinocytes 
and Langerhans cells are known to express these receptors. Skin conditions where 
Toll-like receptors are known to be upregulated include acne, psoriasis, atopic
dermatitis, syphilis, leprosy, Staphylococcus aureus infections, candidiasis, and
herpes simplex and varicella zoster infections. Besides imiquimod, which is the
most successful and more studied topical Toll-like receptor-modulating agent to
date, other topical agents, such as nicotinamide, all-trans retinoic acid,
adapalene, zinc, and sodium tosylchloramide, have also been found to exert some
of their action through Toll-like receptors. Recent topical agents, including
CBT-SL5 and CpG-ODN, are being evaluated for the treatment of inflammatory acne
and skin cancer, respectively, and have demonstrated to be effective in the
treatment of those conditions.


PMCID: PMC2945844
PMID: 20877521 [PubMed - in process]


16. Neurology. 2010 Sep 28;75(13):e55.

Teaching NeuroImages: herpes zoster myelitis.

Moudgil SS.

shyammd.moudgil@stjohn.org

PMID: 20876460 [PubMed - in process]


17. J Neurovirol. 2010 Sep 27. [Epub ahead of print]

Varicella-zoster virus human ganglionic latency: a current summary.

Kennedy PG, Cohrs RJ.

Department of Neurology, Glasgow University, Southern General Hospital, Glasgow, 
Scotland, UK.

Varicella-zoster virus (VZV) is a ubiquitous human herpes virus typically
acquired in childhood when it causes varicella (chickenpox), following which the 
virus establishes a latent infection in trigeminal and dorsal root ganglia that
lasts for the life of the individual. VZV subsequently reactivates, spontaneously
or after specific triggering factors, to cause herpes zoster (shingles), which
may be complicated by postherpetic neuralgia and several other neurological
complications including vasculopathy. Our understanding of VZV latency lags
behind our knowledge of herpes simplex virus type 1 (HSV-1) latency primarily due
to the difficulty in propagating the virus to high titers in a cell-free state,
and the lack of a suitable small-animal model for studying virus latency and
reactivation. It is now established beyond doubt that latent VZV is predominantly
located in human ganglionic neurons. Virus gene transcription during latency is
epigenetically regulated, and appears to be restricted to expression of at least 
six genes, with expression of gene 63 being the hallmark of latency. However,
viral gene transcription may be more extensive than previously thought. There is 
also evidence for several VZV genes being expressed at the protein level,
including VZV gene 63–encoded protein, but recent evidence suggests that
this may not be a common event. The nature and extent of the chronic inflammatory
response in latently infected ganglia is also of current interest. There remain
several questions concerning the VZV latency process that still need to be
resolved unambiguously and it is likely that this will require the use of newly
developed molecular technologies, such as GeXPS multiplex polymerase chain
reaction (PCR) for virus transcriptional analysis and ChIP-seq to study the
epigenetic of latent virus genome ( Liu et al, 2010 , BMC Biol 8: 56).


PMID: 20874010 [PubMed - as supplied by publisher]


18. Am J Infect Control. 2010 Oct;38(8):669-70.

Transmission of varicella-zoster virus originating from a patient with localized 
herpes zoster: Implications for infection control?

Cholongitas E, Ilonidis G.

PMID: 20868936 [PubMed - in process]


19. J Am Geriatr Soc. 2010 Sep;58(9):1799-800. doi: 10.1111/j.1532-5415.2010.03023.x.

Zoster vaccine in older adults.

Fried R.

Comment on:
    J Am Geriatr Soc. 2010 Sep;58(9):1634-41.

PMID: 20863342 [PubMed - indexed for MEDLINE]


20. J Am Geriatr Soc. 2010 Sep;58(9):1634-41. doi: 10.1111/j.1532-5415.2010.03021.x.

Effect of a zoster vaccine on herpes zoster-related interference with functional 
status and health-related quality-of-life measures in older adults.

Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh
SS, Levin MJ, Harbecke RM, Oxman MN; Shingles Prevention Study Group.

Collaborators: Davis LE, Kauffman CA, Keay SK, Marques AR, Soto NE, Brunell P,
Gnann JW, Serrao R, Cotton DJ, Goodman RP, Arbeit RD, Pachucki CT, Levin MJ,
Schmader KE, Keitel WA, Greenberg RN, Morrison VA, Wright PR, Griffin MR,
Simberkoff MS, Yeh SS, Lobo Z, Holodniy M, Loutit J, Betts RF, Gelb LD, Crawford 
GE, Guatelli J, Brooks PA, Neuzil KM, Toney JF.

Durham Veterans Affairs Medical Center Geriatric Research, Education and Clinical
Center and Duke University Medical Centers, Durham, North Carolina, USA.

Comment in:
    J Am Geriatr Soc. 2010 Sep;58(9):1799-800.

OBJECTIVE: To determine the efficacy of a zoster vaccine on herpes zoster
(HR)-related interference with activities of daily living (ADLs) and
health-related quality of life (HRQL). DESIGN: Randomized double-blind placebo
controlled trial. SETTING: Twenty-two U.S. sites. PARTICIPANTS: Thirty eight
thousand five hundred forty-six women and men aged 60 and olcer. MEASUREMENTS: HZ
burden of interference with ADLs and HRQL using ratings from the Zoster Brief
Pain Inventory (ZBPI) and Medical Outcomes Study 12-item Short Form Survey
(SF-12) mental component summary (MCS) and physical component summary (PCS)
scores. Vaccine efficacy was calculated for the modified-intention-to-treat trial
population and solely in participants who developed HZ. RESULTS: For the
modified-intention-to-treat population, the overall zoster vaccine efficacy was
66% (95% confidence interval (CI)=55-74%) for ZBPI ADL burden of interference
score and 55% (95% CI=48-61%) for both the SF-12 MCS and PCS scores. Of
participants who developed HZ, zoster vaccine reduced the ZBPI ADL burden of
interference score by 31% (95% CI=12-51%) and did not significantly reduce the
effect on HRQL. CONCLUSIONS: Zoster vaccine reduced the burden of HZ-related
interference with ADLs in the population of vaccinees and in vaccinees who
developed HZ. Zoster vaccine reduced the effect of HZ on HRQL in the population
of vaccinees but not in vaccinees who developed HZ.


PMCID: PMC2946120 [Available on 2011/9/1]
PMID: 20863322 [PubMed - indexed for MEDLINE]